Welcome to our dedicated page for Organogenesis Holdings SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Organogenesis Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Organogenesis Holdings's regulatory disclosures and financial reporting.
Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant in the form of restricted stock units (RSUs) covering 48,828 shares of Class A common stock. The award was granted at no cash cost per share and represents a compensation-related acquisition, not an open-market purchase.
Each RSU converts into one share of Class A common stock upon vesting. The RSUs vest in full on February 15, 2027, meaning Driscoll will receive the underlying shares only if the vesting conditions are satisfied. Following this grant, his directly held Class A share balance reported in this filing is 215,707 shares.
Giacomin Jon L reported acquisition or exercise transactions in this Form 4 filing.
Organogenesis Holdings Inc. director Jon L. Giacomin reported receiving an equity grant in the form of restricted stock units (RSUs). The award covers 48,828 RSUs, each representing one share of Class A common stock upon vesting. These RSUs vest in full on February 15, 2027, aligning his compensation with long‑term shareholder value. Following this grant, Giacomin directly owns 241,026 shares of Organogenesis Class A common stock.
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an equity award of Class A common stock. He acquired 48,828 shares through a grant of restricted stock units (RSUs) at no cash cost, increasing his directly held stake to 286,014 shares after the transaction.
The RSUs were granted under the Organogenesis 2018 Equity Incentive Plan. Each RSU converts into one share of Class A common stock upon vesting, and the entire award is scheduled to vest in full on February 15, 2027, aligning director compensation with the company’s long-term performance.
Organogenesis Holdings Inc. vice president Antonio S. Montecalvo reported multiple equity compensation awards. On February 18, 2026, he received a stock option for 23,162 shares at an exercise price of $0.00 and restricted stock units for 40,625 shares and 11,218 shares of Class A common stock.
The RSUs were granted under the 2018 Equity Incentive Plan and vest in equal annual installments over four years beginning on February 15, 2026. The option also becomes exercisable in equal annual installments over four years beginning on the same date.
In connection with the vesting and settlement of a 2025 performance share award based on achievement of performance milestones, 3,741 Class A shares were disposed of at $3.84 per share to cover tax withholding, leaving Montecalvo with 226,163 Class A shares held directly.
Organogenesis Holdings Inc. director Gilberto Quintero reported an equity award of 48,828 restricted stock units (RSUs) of Class A common stock under the company’s 2018 Equity Incentive Plan. Each RSU converts into one share upon vesting, and the award vests in full on February 15, 2027. Following this grant, Quintero directly holds 239,073 shares of Class A common stock.
Duraibabu Prathyusha reported acquisition or exercise transactions in this Form 4 filing.
Organogenesis Holdings Inc. director Prathyusha Duraibabu reported an equity award of 48,828 restricted stock units (RSUs) of Class A common stock. The RSUs were granted under the company’s 2018 Equity Incentive Plan at a price of $0.00 per unit, reflecting a compensatory grant rather than an open‑market purchase.
Each RSU represents the right to receive one share of Class A common stock upon vesting, and the award vests in full on February 15, 2027. Following this grant, Duraibabu’s directly held Class A common stock (including underlying RSUs as reported) totals 247,047 shares, highlighting an increase in her equity‑based alignment with shareholders.
Organogenesis Holdings Inc. director Garrett Lustig reported an equity award from the company. He acquired 48,828 shares of Class A common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share, bringing his direct holdings to 125,742 shares.
Each RSU represents the right to receive one share of Organogenesis Class A common stock upon vesting. According to the grant terms, all of these RSUs vest in full on February 15, 2027, aligning Lustig’s compensation with the company’s long-term performance.
Organogenesis Holdings Inc. director Michele Ilene Korfin received an equity grant in the form of restricted stock units (RSUs). The award covers 48,828 shares of Class A common stock at a stated price of $0.00 per share.
Each RSU converts into one share of Class A common stock upon vesting, and the RSUs vest in full on February 15, 2027. After this grant, Korfin’s directly held Class A common stock reported in the filing totals 239,073 shares.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported four tax-withholding dispositions of Class A common stock on February 15, 2026, at $3.73 per share. After these transactions related to tax obligations, he directly owned 506,647 Class A shares.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported several insider transactions involving Class A common stock. On February 15, 2026, he disposed of shares in four separate transactions coded “F,” which indicates shares were delivered to cover a tax liability or exercise price.
Across these tax-withholding dispositions, shares were transferred at a reported price of $3.73 per share. After the final transaction, Bilbo continued to directly own 884,648 shares of Class A common stock, reflecting a substantial remaining equity stake in the company.